Korea's fertility-treatment boom is landing in paediatric urology waiting rooms

South Korea's Ministry of Health and Welfare disclosed on the 14th that births through fertility treatment rose from 23,122 in 2022 to 48,981 last year, taking their share of all newborns from 9.3% to 19.2% ^[1][2]. Paediatric urology caseloads moved in the same direction: the Health Insurance Review and Assessment Service recorded undescended testicles in boys under five rising 34.8%, from 3,971 cases to 5,351 ^[3].

The demographic shift is larger than the headline percentage suggests. Treatment births grew by 25,859, or about 112% ^[9]. Back out the implied denominator from the reported shares and total newborns were roughly 248,600 in 2022 and roughly 255,100 last year, an increase of about 2.6% ^[10]. So the share did not double because the birth base collapsed. It doubled because treatment volume did.

The clinical link is asserted rather than quantified in the material. For a boy's genitals to form normally, male hormones must act properly during fetal reproductive development, and the female hormones used to sustain pregnancy during fertility procedures may interfere ^[6]. Park Kwan-jin, a professor of paediatric urology at Seoul National University Hospital, called the link between fertility treatment and these disorders "an established fact," pointing to progesterone and other hormones used to sustain pregnancy ^[7]. Park also said cutting back on hormone administration can affect the maintenance of pregnancy, so the practical response is surgery or other treatment at the appropriate time once a condition is identified after birth ^[8].

Operators should read the two growth rates carefully before extrapolating. Treatment births grew roughly 3.2 times faster than the undescended-testicle caseload ^[12], and the caseload rose by 1,380 cases in absolute terms ^[11]. The under-five band also spans five birth cohorts, so last year's count reflects several years of births, not one ^[13]. None of the figures cited establish a per-birth incidence rate for treatment-conceived boys against naturally conceived boys ^[14]. Anyone building a thesis on a dose-response relationship is filling in that gap themselves.

What the numbers do support is a volume story with unusual predictability. Undescended testicles and hypospadias are congenital conditions identified at or soon after birth ^[4][5], and the intervention is time-sensitive ^[8]. That combination -- a defined cohort, early detection, a surgical window -- is the kind of demand profile that supports staffed capacity rather than opportunistic referral. Roughly 5,351 under-five cases of one condition alone ^[3] is a small absolute market by hospital standards, which is precisely why it sits outside most healthcare funds' screens while fertility clinics themselves attract capital.

Three things to watch. First, whether the ministry or HIRA publishes incidence split by conception method, which would turn a correlation into a sizeable number. Second, hypospadias case counts, which the reported data leaves unquantified ^[5]. Third, paediatric urology specialist supply and surgical scheduling, since the practical response Park describes only works if the appropriate time can actually be met ^[8].